MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles
MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles
复制标题
DOI：
10.1007/s13277-014-2133-4
复制
发表时间：
2014-09-01
期刊：
影响因子：
--
通讯作者：
Ji, Dongdong
中科院分区：
文献类型：
--
作者：
Ding, Zhongyang;Wu, Haorong;Ji, Dongdong
据报道，失调的microrna （mirna）与胰腺癌（PaC）有关，这表明它们可能作为PaC的有用的新型诊断生物标志物。已经进行了各种研究来研究mirna对PaC的诊断价值，但得到了相互矛盾的结果。因此，本荟萃分析旨在全面定量评估mirna对PaC的潜在诊断价值。我们系统地检索PubMed、Embase、谷歌Scholar、Cochrane Library和Chinese National Knowledge Infrastructure，检索有关mirna对PaC诊断价值的出版物，不受语言限制。使用修订后的诊断准确性研究质量评估（QUADAS-2）对每项研究的质量进行评分。采用综合接收算子特征曲线等参数对试验总体性能进行检验。异质性检验采用I(2)检验，发表偏倚检验采用Deek的漏斗图不对称检验。本荟萃分析包括18篇文章，共2036例患者和1444例对照。合并敏感性为82% (95% CI, 78- 86%)；特异性为77% (95% CI, 73 ~ 81%)；PLR为3.6 (95% CI, 3.0-4.4)；NLR为0.23 (95% CI, 0.18-0.29)；DOR为16 (95% CI, 10-24)；AUC为0.86 （95% CI, 0.83-0.89）。还进行了亚组分析，并揭示了一些亚组之间存在显著差异：基于多mirna谱分析的检测、非血液检测和基于健康对照的研究都显示出PaC诊断的准确性高于相应的检测。这项荟萃分析表明，使用mirna对PaC具有潜在的诊断价值，具有相对较高的敏感性和特异性，特别是使用多种mirna来区分PaC患者和健康个体。mirna对PaC的诊断价值有待进一步的前瞻性研究。
Dysregulated microRNAs (miRNAs) have been reported to be associated with pancreatic cancer (PaC), suggesting that they may serve as useful novel diagnostic biomarkers for PaC. Various studies have been performed to investigate the diagnostic value of miRNAs for PaC but have obtained conflicting results. Therefore, this meta-analysis aims to comprehensively and quantitatively evaluate the potential diagnostic value of miRNAs for PaC. We systematically searched PubMed, Embase, Google Scholar, Cochrane Library, and Chinese National Knowledge Infrastructure for publications concerning the diagnostic value of miRNAs for PaC without language restriction. The quality of each study was scored using the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The summary receiver operator characteristic curve and other parameters were applied to check the overall test performance. Heterogeneity was tested with the I (2) test and publication bias was tested with the Deek's funnel plot asymmetry test. This meta-analysis included 18 articles with a total of 2,036 patients and 1,444 controls. The pooled sensitivity was 82 % (95 % CI, 78-86 %); the specificity was 77 % (95 % CI, 73-81 %); the PLR was 3.6 (95 % CI, 3.0-4.4); the NLR was 0.23 (95 % CI, 0.18-0.29); the DOR was 16 (95 % CI, 10-24); and the AUC was 0.86 (95 % CI, 0.83-0.89). Subgroups analyses were also performed and revealed that there were significant differences between some subgroups: the multiple-miRNAs profiling-based assays, non-blood-based assays, and healthy control-based studies all showed higher accuracies in diagnosing PaC than that of their counterparts. This meta-analysis suggests that the use of miRNAs has potential diagnostic value with a relatively high sensitivity and specificity for PaC, particularly the use of multiple miRNAs for discriminating PaC patients from healthy individuals. More prospective studies on the diagnostic value of miRNAs for PaC are needed in the future.